Abstract
Pure adenocarcinomas of the bladder are a very rare entity. It is important to understand the distinctions between the different types of adenocarcinomas that may be found in the bladder, as it may have an impact on their treatment. Urachal carcinomas, traditionally found in the midline or dome of the bladder, require a surgical procedure that is different from the typical cystectomy. Metastatic adenocarcinomas can occur from direct extension of local organs including the colon and rectum, from drop implants/peritoneal seeding from other adenocarcinomas of the abdominal cavity, and even from hematogenous metastases from primary sites both within and outside the abdominal cavity. Often, a careful medical history of previous cancer, clinical symptoms which are not typically associated with a bladder primary, and radiological findings suggestive of other potential primaries can aid in diagnosing a metastasis to the bladder. Adenocarcinomas of the urethra, which are addressed in a separate chapter, can also invade the bladder base and trigone secondarily. Only when none of these above findings are present should one consider the patient a true primary adenocarcinoma of the bladder.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer. 1991;67:2165–72.
Lughezzani G, Sun M, Jeldres C, et al. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology. 2010;75:376–81.
Smeulders N, Woodhouse CR. Neoplasia in adult exstrophy patients. BJU Int. 2001;87:623–8.
Allen TD, Henderson BW. Adenocarcinoma of the bladder. J Urol. 1965;93:50–6.
Mostofi FK. Potentialities of bladder epithelium. J Urol. 1954;71:705–14.
Mai KT, Yazdi HM, Perkins DG, et al. Multicentric clear cell adenocarcinoma in the urinary bladder and the urethral diverticulum: evidence of origin of clear cell adenocarcinoma of the female lower urinary tract from Mullerian duct remnants. Histopathology. 2000;36:380–2.
Zaghloul MS, Nouh A, Nazmy M, et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol. 2006;24:13–20.
Dayyani F, Czerniak BA, Sircar K, et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013;189:1656–61.
Ro JY, Shen SS, Lee HI, et al. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol. 2008;32:752–7.
Lopez-Beltran A, Luque RJ, Quintero A, et al. Hepatoid adenocarcinoma of the urinary bladder. Virchows Arch. 2003;442:381–7.
Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol. 2001;25:1380–7.
Torenbeek R, Lagendijk JH, Van Diest PJ, et al. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology. 1998;32:20–7.
Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303–10.
Thomas AA, Stephenson AJ, Campbell SC, et al. Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. Hum Pathol. 2009;40:108–16.
El-Mekresh MM, El-Baz MA, Abol-Enein H, et al. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol. 1998;82:206–12.
Zaghloul MS, Abdel Aziz S. Primary adenocarcinoma of the urinary bladder: risk factors and value of postoperative radiotherapy. J Egypt Natl Canc Inst. 2003;15:193–200.
Siefker-Radtke AO, Gee J, Shen Y, et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 2003;169:1295–8.
Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007;69:255–9.
Sheldon CA, Clayman RV, Gonzalez R, et al. Malignant urachal lesions. J Urol. 1984;131:1–8.
Wright JL, Porter MP, Li CI, et al. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer. 2006;107:721–8.
Henly DR, Farrow GM, Zincke H. Urachal cancer: role of conservative surgery. Urology. 1993;42:635–9.
Gupta S, Bhaijee F, Harmon EP. Mucinous neoplasm arising in a urachal cyst: a first in the pediatric population. Urology. 2014;83:455–6.
Sirintrapun SJ, Ward M, Woo J, et al. High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations. Hum Pathol. 2014;45:327–30.
Schubert GE, Pavkovic MB, Bethke-Bedurftig BA. Tubular urachal remnants in adult bladders. J Urol. 1982;127:40–2.
Johnson DE, Hodge GB, Abdul-Karim FW, et al. Urachal carcinoma. Urology. 1985;26:218–21.
Siefker-Radtke A. Urachal adenocarcinoma: a clinician’s guide for treatment. Semin Oncol. 2012;39:619–24.
Takeuchi M, Matsuzaki K, Yoshida S, et al. Imaging findings of Urachal mucinous cystadenocarcinoma associated with pseudomyxoma peritonei. Acta Radiol. 2004;45:348–50.
Ashley RA, Inman BA, Sebo TJ, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006;107:712–20.
Bruins HM, Visser O, Ploeg M, et al. The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol. 2012;188:1102–7.
Herr HW, Bochner BH, Sharp D, et al. Urachal carcinoma: contemporary surgical outcomes. J Urol. 2007;178:74–8. discussion 78.
Molina JR, Quevedo JF, Furth AF, et al. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. Cancer. 2007;110:2434–40.
Lane V. Prognosis in carcinoma of the urachus. Eur Urol. 1976;2:282–3.
Kakizoe T. Adenocarcinoma of urachus. Report of 7 cases and review of literature. Urology. 1983;21:360–6.
Logothetis CJ, Samuels ML, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology. 1985;26:252–5.
Siefker-Radtke AO, Millikan RE, Tu S-M, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2002;20:1361–7.
Tannir NM, Thall PF, Ng CS, et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008;180:867–72. discussion 872.
Tu SM, Hossan E, Amato R, et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol. 1995;154:1719–22.
Yanagihara Y, Tanji N, Miura N, et al. Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer. Chemotherapy. 2013;59:402–6.
Kojima Y, Yamada Y, Kamisawa H, et al. Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy. Int J Urol. 2006;13:1123–5.
Kume H, Tomita K, Takahashi S, et al. Irinotecan as a new agent for urachal cancer. Urol Int. 2006;76:281–2.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Siefker-Radtke, A.O. (2016). Urachal and Non-urachal Adenocarcinomas of the Bladder. In: Pagliaro, L. (eds) Rare Genitourinary Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-30046-7_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-30046-7_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-30044-3
Online ISBN: 978-3-319-30046-7
eBook Packages: MedicineMedicine (R0)